What is Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (688016.SS) StockRank?

MoatMap's StockRank for Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS) is 88/100, with a Strong Buy signal. This is a composite score combining Quality (77), Value (42), and Momentum (57) factor ranks across MoatMap's 20,000+ stock universe.

Does Shanghai MicroPort Endovascular MedTech Co., Ltd. have an economic moat?

Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS) has a Quality factor score of 77/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Shanghai MicroPort Endovascular MedTech Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS) is Strong Buy, based on a StockRank of 88/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Shanghai MicroPort Endovascular MedTech Co., Ltd. in?

Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS) operates in the Healthcare sector, specifically the Medical Devices industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

688016.SS

STRONG BUYREMOVE

Shanghai MicroPort Endovascular MedTech Co., Ltd. · Healthcare · China · $1.9B · Avg Vol: $28M/d

StockRank

P/E (TTM)

18.7x

ROE

14.3%

D/E

0.0x

Dividend %

2.5%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

While operating in the medical device space, Shanghai MicroPort Endovascular does not align with our core high-conviction CDMO or localization themes, and faces domestic policy headwinds in China regarding volume-based procurement.

COMPANY DESCRIPTION

Shanghai MicroPort Endovascular MedTech Co., Ltd. develops and manufactures minimally invasive interventional medical devices for aortic and peripheral vascular diseases. The company is the market leader in China's aortic stent graft market, successfully competing against major multinational medical device firms. Its competitive moat is reinforced by a robust pipeline of innovative, patented products and an extensive clinical trial and hospital distribution network across China.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	132M	175M	178M	200M	14.6%
EPS	0.49	1.01	0.60	0.69	11.8%
Shares	107M	123M	123M	123M	+14.9%
Debt	6M	5M	6M	2M	-28.6%
Equity	254M	568M	560M	602M	33.3%
Op CF	49M	83M	55M	85M	19.7%
Inv CF	-65M	-26M	-108M	-57M	—
Fin CF	-24M	237M	-79M	-52M	—

PRICE (1M)-12.4%

SMA 50SMA 200

$13.16

RSI (14)

24.4

52W High

$17.96

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

15.5%85.7

ROE

14.3%81.3

GP/Assets

21.4%49.3

Op. Margin

48.8%98.1

FCF/Assets

5.2%71.5

Piotroski

—55.7

Int. Cover

50.0x91.5

D/E Ratio

0.00x95.1

Current Ratio

6.94x80.0

Value

P/E (TTM)

18.7x60.4

EV/EBITDA

13.3x32.2

P/FCF

355.7x23.7

P/B

2.6x45.2

P/S

8.1x29.8

Div Yield

2.5%58.1

Momentum

52W High %

73%61.8

RS 6M

-13%65.3

SMA 50/200

0.99x59.5

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+22%35.0

Q Growth

19%63.1

FUNDAMENTALS

Market Cap

$1.9B

P/E (Forward)

15.4x

Gross Margin

71.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688016.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
688016.SS	Shanghai MicroPort Endovascular MedTech Co., Ltd.(you)	$1.9B	88	STRONG BUY
301087.SZ	Cofoe Medical Technology Co.,Ltd.	$1.6B	92	STRONG BUY
300529.SZ	Jafron Biomedical Co.,Ltd.	$2.1B	80	STRONG BUY
600587.SS	Shinva Medical Instrument Co.,Ltd.	$1.2B	84	STRONG BUY
603658.SS	Autobio Diagnostics Co., Ltd.	$2.8B	94	STRONG BUY
300206.SZ	Edan Instruments, Inc.	$1.2B	94	STRONG BUY
1302.HK	LifeTech Scientific Corporation	$932M	84	STRONG BUY
2190.HK	Zylox-Tonbridge Medical Technology Co., Ltd.	$853M	82	STRONG BUY
1763.HK	China Isotope & Radiation Corporation	$734M	85	STRONG BUY
603387.SS	Getein Biotech, Inc	$668M	90	STRONG BUY

Peer medians: ROE 4.7% · P/E 27.9x · Gross margin 53.0%

Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS) — Stock Score Summary

Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS) has a MoatMap StockRank of 88/100 based on Quality (77/100), Value (42/100), and Momentum (57/100) factor scores. The current signal is STRONG BUY. While operating in the medical device space, Shanghai MicroPort Endovascular does not align with our core high-conviction CDMO or localization themes, and faces domestic policy headwinds in China regarding volume-based procurement.

Key Financial Metrics

Price	$13.16
Market Cap	$1.9B
P/E (TTM)	18.71
P/E (Forward)	15.36
Price/Book	2.62
Return on Equity	14.3%
Return on Invested Capital	15.5%
Debt/Equity	0.28
Gross Margin	71.3%
Operating Margin	48.8%
Revenue Growth	11.5%
Dividend Yield	2.5%
Free Cash Flow	$5M

Shanghai MicroPort Endovascular MedTech Co., Ltd. operates in the Medical Devices industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Shanghai MicroPort Endovascular MedTech Co., Ltd.’s (688016.SS) StockRank?: MoatMap’s StockRank for Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS) is 88/100, with a Strong Buy signal. It is a composite of Quality (77), Value (42), and Momentum (57) factor ranks across MoatMap’s 20,000+ stock universe.
Does Shanghai MicroPort Endovascular MedTech Co., Ltd. have an economic moat?: Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS) has a Quality factor score of 77/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Shanghai MicroPort Endovascular MedTech Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS) is Strong Buy, based on a StockRank of 88/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Shanghai MicroPort Endovascular MedTech Co., Ltd. in?: Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS) operates in the Healthcare sector, specifically the Medical Devices industry (China).